Combining SBRT with DDR-targeted agents (e.g., ATM, DNA-PK, or PARP inhibitors) and immunomodulatory approaches holds promise for overcoming resistance and improving outcomes in prostate cancer. This evidence concerns the gene ATM and prostate carcinoma.